Horizon Healthcare (pvt.) ltd.
Private pharmaceutical manufacturer · Taxila · Pakistan
Pakistan pharmaceutical manufacturer with a DRAP-listed manufacturing facility in Taxila and a broad branded product portfolio.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Private pharmaceutical manufacturer
- Address
- Plot No. 35-A, Small Industrial Estate, Taxila, Rawalpindi, Pakistan
- Website
- horizonpharma.net.pk ↗
- Corporate source details checked
- 21 Aug 2026
- Corporate profile completeness
- 63%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Ansamic | Tranexamic acid | 250 mg | Injection | 10's | 085355 | PKR 913.57 | PKR 91.36/vial/unit | 57% above median |
| Ansamic | Tranexamic acid | 500 mg/5 mL (100 mg/mL) | Solution for injection | 10's | 085356 | PKR 1,695.50 | PKR 169.55/vial/unit | No comparator |
| Ansamic | Tranexamic acid | 500 mg | Injection | 10's | 085356 | PKR 1,695.50 | PKR 169.55/vial/unit | Near median |
| Ardcil | Piperacillin + tazobactam | 2 g + 0.25 g | Injection | 1's | 119090 | PKR 678.20 | PKR 678.20/vial/unit | Near median |
| Ardcil | Piperacillin + tazobactam | 4 g + 0.5 g | Injection | 1's | 119091 | PKR 1,541.90 | PKR 1,541.90/vial/unit | Near median |
| Artezon | Artesunate | 30 mg | Injection | 1's | 099989 | PKR 148.70 | PKR 148.70/vial/unit | Near median |
| Artezon | Artesunate | 60 mg | Injection | 1's | 099990 | PKR 247.84 | PKR 247.84/vial/unit | Near median |
| Artezon | Artesunate | 120 mg | Injection | 1's | 099991 | PKR 413.06 | PKR 413.06/vial/unit | Near median |
| Binalfine W/W | Terbinafine | 1 % | Cream | 10gm | 085350 | PKR 294.42 | PKR 29.44/g | Near median |
| Bruwell | Ibuprofen | 100 mg/5 mL | Oral suspension | 60ml | 078762 | PKR 51.53 | PKR 0.86/mL | Near median |
| Bruwell | Ibuprofen | 100 mg/5 mL | Oral suspension | 120ml | 078762 | PKR 105.69 | PKR 0.88/mL | Near median |
| Budenox | Budesonide + Formoterol | 200 mcg + 6 mcg | Inhalation capsule | 30's | 119288 | PKR 550.54 | PKR 18.35/capsule | Near median |
| Budenox | Budesonide + Formoterol | 400 mcg + 12 mcg | Inhalation capsule | 30's | 119289 | PKR 917.56 | PKR 30.59/capsule | 11% above median |
| Cipness | Ciprofloxacin | 250 mg | Tablet | 10's | 078738 | PKR 259.32 | PKR 25.93/tablet | Near median |
| Cipness | Ciprofloxacin | 500 mg | Tablet | 10's | 078739 | PKR 428.86 | PKR 42.89/tablet | Near median |
| Claxizon | Clarithromycin | 250 mg | Tablet | 10's | 113832 | PKR 478.73 | PKR 47.87/tablet | Near median |
| Claxizon | Clarithromycin | 500 mg | Tablet | 10's | 113833 | PKR 797.88 | PKR 79.79/tablet | Near median |
| Colistizon | Colistimethate sodium | 1 MIU (≈34 mg colistin base activity) | Injection | 1’s | 116306 | PKR 1,852.99 | PKR 1,852.99/vial/unit | 54% above median |
| Colistizon | Colistimethate sodium | 2 MIU (≈68 mg colistin base activity) | Injection | 1’s | 116703 | PKR 3,088.69 | PKR 3,088.69/vial/unit | 54% above median |
| Colistizon | Colistimethate sodium | 4.5 MIU (≈150 mg colistin base activity) | Injection | 1’s | 116704 | PKR 3,474.35 | PKR 3,474.35/vial/unit | 23% below median |
| DITS | Omeprazole | 20 mg | Capsule | 30's | 078759 | PKR 566.49 | PKR 18.88/capsule | Near median |
| DITS | Omeprazole | 40 mg | Capsule | 30's | 078760 | PKR 983.38 | PKR 32.78/capsule | 5% below median |
| Dits-S 40 | Omeprazole + Sodium bicarbonate | 40 mg + 1100 mg | Capsule | 14's | 089958 | PKR 489.25 | PKR 34.95/capsule | 21% above median |
| Doetum | Ascorbic acid | 500 mg | Chewable tablet | 40’s | 107322 | PKR 74.87 | PKR 1.87/tablet | 41% above median |
| Emjure | Empagliflozin | 10 mg | Tablet | 14's | 109668 | PKR 1,261.97 | PKR 90.14/tablet | 9% above median |
| Emjure | Empagliflozin | 25 mg | Tablet | 14's | 109669 | PKR 1,510.49 | PKR 107.89/tablet | 8% above median |
| Endtron | Ondansetron | 8 mg | Tablet | 10's | 098061 | PKR 1,776.16 | PKR 177.62/tablet | 6% above median |
| Endtron | Ondansetron | 8 mg/4 mL | Injection | 4ml*5s | 103260 | PKR 5,228.20 | — | No comparator |
| Fanaze | Fluconazole | 150 mg | Capsule | 1's | 116493 | PKR 275.27 | PKR 275.27/capsule | Near median |
| Ferdina | Bisoprolol fumarate | 2.5 mg | Tablet | 14’s | 105866 | PKR 65.12 | PKR 4.65/tablet | 10% above median |
| Ferdina | Bisoprolol fumarate | 5 mg | Tablet | 20’s | 105867 | PKR 249.34 | PKR 12.47/tablet | 6% above median |
| Fleet | Clopidogrel | 75 mg | Tablet | 10’s | 089948 | PKR 279.26 | PKR 27.93/tablet | Near median |
| Flimivir | Oseltamivir | 75 mg | Capsule | 10's | 095395 | PKR 1,548.97 | PKR 154.90/capsule | 29% above median |
| Iboxime | Cefixime | 400 mg | Capsule | 5's | 098053 | PKR 592.03 | PKR 118.41/capsule | Near median |
| Iboxime Dry | Cefixime | 100 mg/5 mL | Dry suspension | 30ml | 098048 | PKR 330.39 | PKR 11.01/mL | 5% above median |
| Iboxime Dry | Cefixime | 200 mg/5 mL | Dry suspension | 30ml | 098049 | PKR 404.33 | PKR 13.48/mL | Near median |
| Iromose-F | Iron polymaltose complex + Folic acid | 100 mg + 0.35 mg | Tablet | 30’s | 078741 | PKR 398.61 | PKR 13.29/tablet | Near median |
| Isaac | Voriconazole | 50 mg | Tablet | 10’s | 105871 | PKR 797.88 | PKR 79.79/tablet | Near median |
| Iveetin | Ivermectin | 3 mg | Tablet | 20’s | 115587 | PKR 638.30 | PKR 31.92/tablet | Near median |
| Lacura | Ceftriaxone | 1 g | Injection | 1's | 098043 | PKR 662.97 | PKR 662.97/vial/unit | 10% above median |
| Lacura | Ceftriaxone | 500 mg | IM injection | 1's | 098044 | PKR 351.10 | PKR 351.10/vial/unit | 6% above median |
| Lacura | Ceftriaxone | 250 mg | IM injection | 1's | 098045 | PKR 208.59 | PKR 208.59/vial/unit | 6% above median |
| Lacura | Ceftriaxone | 1 g | Injection | 1's | 098050 | PKR 662.97 | PKR 662.97/vial/unit | 10% above median |
| Lacura | Ceftriaxone | 500 mg | Injection | 1's | 098051 | PKR 351.10 | PKR 351.10/vial/unit | 8% above median |
| Lacura | Ceftriaxone | 250 mg | Injection | 1's | 098052 | PKR 208.59 | PKR 208.59/vial/unit | 9% above median |
| Latanoprost-T | Latanoprost + Timolol | 50 mcg/mL + 5 mg/mL | Ophthalmic solution | 2.5ml | 119400 | PKR 759.13 | PKR 303.65/mL | No comparator |
| Latazon 0.005% w/v Eye | Latanoprost | 0.005 % | Ophthalmic drops | 2.5ml | 119355 | PKR 717.32 | PKR 286.93/mL | 7% below median |
| Lemit | Levofloxacin | 250 mg | Tablet | 10's | 078745 | PKR 498.68 | PKR 49.87/tablet | Near median |
| Lemit | Levofloxacin | 500 mg | Tablet | 10's | 078746 | PKR 829.80 | PKR 82.98/tablet | Near median |
| Listono | Colistimethate sodium | 1 MIU | Injection | 1's | 119201 | PKR 1,199.81 | PKR 1,199.81/vial/unit | 28% below median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.